Mumbai: Indian drugmaker Lupin will sell the generic version of oral antibiotic Solodyn in the United States (US) after it received regulatory nod for the $750-million-a-year drug, it said on Friday.
Solodyn, made by US-based Medicis Pharmaceutical Corp, is used to treat pimples and red bumps.
Lupin had settled a litigation with Medicis over the drug in July paving way for the US launch of the copy-cat version.
A file photo of tablets
The settlement allowed Lupin to sell the antibiotic November onwards and also sell the same drug with different strengths from 2018 and 2019 onwards.
The current approval is for 45 mg, 55 mg, 90 mg and 135 mg dosage strengths, it said.
Lupin and Medicis also share a licensing pact to develop multiple therapeutic compounds using the Indian company’s formulation technologies.
At 11:40 am, shares of Lupin, which have lost 9% in value in last year, were trading at Rs 467.10, up 0.34% in a choppy Mumbai market.